Five Prime Therapeutics (FPRX) Misses Q3 EPS by 30c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Five Prime Therapeutics (FPRX) Comments From Jefferies 'Data Not As Strong As We Like To See'
November 7, 2017 11:51 AM ESTJefferies maintains Buy on Five Prime Therapeutics (NASDAQ: FPRX) price target of $52.00.
Analyst Eun Yang says the high rates of cabira-associated SAEs are concerning and chooses to await full data presentation at SITC on this coming SAturday before revisiting the... More
Five Prime Therapeutics (FPRX) Selloff Unfounded - Nomura/Instinet
November 7, 2017 11:14 AM ESTNomura/Instinet maintains Buy on Five Prime Therapeutics (NASDAQ: FPRX) price target of $94.00.
Analyst Chris Marai defends the name noting durable IP activity is evident. The analyst reminds clients that cabria is also mechanistically more likely to price benefit to pancreatic patients in... More
